Product Description
Our lead discovery compound has activity against the 26S proteasome, one of the beneficial effects of blocking the proteasome is to inhibit the transcription factor nuclear factor kappa beta (NFkB), which is a potent mediator of inflammation. NFkB has already been shown to be a major, if not the major mediator of skin diseases including Rosacea, Psoriasis, and Acne. In these conditions, inflammation, excess blood vessels, and the enzymes that digest elastic fibers in the skin, are mediated by NFkB. Currently, there are no topical therapies to address proteasomes. (Sourced from: https://accuitis.com/our-pipeline.html)
Mechanisms of Action: IL6 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Emory University
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Rosacea
Phase 1: Acquired Immunodeficiency Syndrome|Papilloma|HIV Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06233331 |
STUDY00006195 | P1 |
Not yet recruiting |
Acquired Immunodeficiency Syndrome|Papilloma|HIV Infections |
2027-12-01 |
2026-05-09 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT03064438 |
ACU-D1 | P2 |
Completed |
Rosacea |
2018-06-05 |
2021-08-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|